Like their human counterparts, animals can also fall victim to bacterial infections. Many companion animals suffer from otitis or pyoderma, whereas livestock is also vulnerable to various contagious bacterial infections.
The widespread use of antibiotics in industrial farming as growth promotors has generated a rise in the number of antibiotic resistant pathogens resulting in ineffective antibiotics in many fields.
Selective breeding has played a role by reducing the genetic variety within a particular animal population. Once an infection strikes it is able to spread quickly endangering the livestock as a whole. In the last years, entire herds of dairy cows had to be culled because of simple infections. Additionally, bacterial infections cause the death of large shrimp populations in aquaculture.
The effects of both selective breeding and antibiotic resistance are becoming more and more obvious. Especially in livestock farming, the situation is quite difficult. On the one hand, the demand for affordable food is increasing worldwide, but on the other hand, development of new antibiotic technologies is reserved for human pharma.
This is a problem that is only going to get worse.
Bacteria do not respect national regulations and borders as currently shown by a colistin resistant E.coli strain harbouring the mcr-1 gene spreading around the globe after first appearance in Chinese pigs.
Even subinhibitory concentrations of antibiotics lead to the exchange of resistance genes between bacterial cells. The slow degradation of antibiotics and the resulting accumulation in the environment provokes selective pressure that is responsible for the development of further resistant microbes in the upcoming years, even if all antibiotics are banned today.
Artilysin®s are the next generation of antimicrobials in veterinary applications.
A balanced bacterial flora is the prerequisite for a robust animal health. The specific mode of action of Artilysin®s supports the preservation of the microbiome and in parallel eliminates pathogenic bacteria efficiently. Numerous trials supervised by veterinaries proofed the fast and lasting treatment in various fields of applications. For example, chronic pyoderma ineffectively treated for several months with conventional antibiotics were successfully cured by Artilysin®s within a couple of days. The extraordinary low relapse rate illustrates the ability of Artilysin®s to completely eliminate the pathogenic population including persisters.